• Alias: BAY 43-9006
    • Orally bioavailable inhibitor of RAF, VEGFR, PDGFR-β, and RET
    • FDA approved for renal cell and HCC
    • Recommended dose: 400 mg PO twice daily without food (at least 1 hour before of 2 hours after a meal)
    • Half-life: 25 to 48 hours
    • Metabolism: UGT1A1 inhibitor; a weak substrate of CYP3A4
    • Common side effects: Rash, redness, itching, or peeling of skin, alopecia, diarrhea, nausea/vomiting, anorexia, abdominal pain, fatigue
    • Clinical pearls: Avoid direct sunlight, use moisturizers after bathing, use mild soap for bathing, and antihistamine for itching. Monitor the patient’s blood            atient on home monitoring. Monitor PT/INR closely for patients taking coumadin.
    Other topics in Targeted and Immunotherapy Agents